Daily mushroom and microalgae powder for gut comfort and mood
Official title: Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris) in Healthy Adults Experiencing Minor Gastrointestinal Discomfort: A 30-Day, Two-Arm, Open-Label Study
Run by Koralo GmbH · NCT07407777 · Data updated 2026-11-12
This 30-day remote study will test whether a daily powdered blend made from oyster mushroom mycelium, microalgae, and bamboo fiber improves gut comfort and mood in generally healthy adults with mild gastrointestinal discomfort.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Koralo GmbH Industry-sponsored |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | January 19, 2026 |
| Main results expected | May 19, 2026 |
| Study ends | May 19, 2026 |
| Registry record updated | February 12, 2026 |
| Trial ID | NCT07407777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are generally healthy adults (18–65) who experience minor gastrointestinal discomfort at least twice weekly for three months or more, can consume a daily powdered beverage, and have access to a smartphone or computer for remote participation.
✕Probably not a fit
People with diagnosed gastrointestinal diseases (for example IBS, IBD, or GERD requiring medication), those on recent medications affecting gut function or mood, pregnant or breastfeeding individuals, or those with major chronic conditions are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a 30-day, two-arm, open-label dietary intervention enrolling 80 adults aged 18–65 who report minor, non-clinical gastrointestinal discomfort. Participants are randomized in an unbalanced allocation to a high-dose arm (4,000 mg/day, n=50) or a low-dose arm (600 mg/day, n=30) and consume the powdered product once daily mixed into a beverage. Outcomes include the Gastrointestinal Symptom Rating Scale (GSRS) and the Profile of Mood States 2 Short Form (POMS-2-SF) measured at baseline, day 15, and day 30, with no invasive procedures or biological sampling. The product is a cGMP-manufactured, food-grade blend from co-fermented Pleurotus pulmonarius mycelium and Chlorella vulgaris microalgae with bamboo fiber and flavoring, deployed via a fully remote platform.
Why it matters
Potential benefit: If successful, this could offer a convenient dietary option to reduce minor gut discomfort and modestly improve mood for people with mild symptoms.
How similar studies have gone: This exact co-fermented mushroom–microalgae blend is novel with limited direct clinical data, although separate small studies of mushroom extracts or microalgae supplements have suggested modest gut or mood effects.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults aged 18 years or older Generally healthy individuals Experience minor, non-clinical gastrointestinal discomfort at least twice per week for ≥3 months Willing to consume the study product once daily for 30 days Able to dissolve and consume the powdered product in a beverage Able to read, understand, and complete electronic questionnaires in English Access to a smartphone or computer for study participation Provide electronic informed consent Exclusion Criteria: * Diagnosed gastrointestinal disease (e.g., IBS, IBD, GERD requiring medication) Use of medications affecting gastrointestinal function or mood within the past 30 days Initiation of new gut-, immune-, or mood-related supplements within 15 days prior to study start Known allergy or sensitivity to study product components Pregnancy or breastfeeding Major chronic medical condition that could interfere with study participation or data interpretation Participation in another interventional clinical study within the past 30 days Inability or unwillingness to comply with study procedures
Where it's running
-
Alethios, Inc.
San Francisco, California, United States Recruiting
Study contacts
- Study coordinator: Guido Albanese, PhD
- Email: guido@koralo-foods.com
- Phone: +49 163 9144333
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Probiotic Supplement for Digestive Comfort in Healthy Women
This study tests whether a daily probiotic capsule can reduce gas and bloating in healthy women, compared with a placebo, over eight weeks.
-
LcS-fermented milk for constipation in Filipino adults
This trial will test whether a daily probiotic drink containing Lacticaseibacillus paracasei strain Shirota (LcS) helps Filipino adults with constipation get softer stools and more regular bowel movements and reduce gastrointestinal discomfort.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.